Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Zynerba Pharmaceuticals, Inc. Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions October 04, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 September 29, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium September 14, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting August 08, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting July 25, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting June 28, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 20, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting June 13, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting May 23, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights May 15, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference April 12, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference April 05, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights March 28, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank March 13, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference March 07, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference March 01, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome January 11, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome December 21, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology December 05, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology November 29, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders November 28, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome November 15, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights November 14, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome November 02, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit October 17, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit October 10, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ October 06, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference September 29, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Tickers ZYNE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.